| Developers: | Quantum Surgical |
| Date of the premiere of the system: | September 2023 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
Content |
2025: Incorrect execution of operations
In mid-June 2025, it became known that the Epione robotic surgical system may not perform operations correctly under certain conditions. This can cause internal damage to the patient.
The Epione robot was developed by the French company Quantum Surgical. The platform is a percutaneous ablation system that uses a robotic arm, navigation module and camera. Epione provides early and minimally invasive treatment for abdominal tumors: The robot inserts a needle through the skin into the neoplasm and destroys it. The system allows surgeons to treat unresectable tumors, including those that are particularly difficult to access because of size or location. Epione can be used in the treatment of liver, kidney and pancreatic cancers, as well as to remove malignancies in the lungs.
The detected problem is due to a software error. It has been established that in a certain situation Epione can place its tool in the wrong position. Quantum Surgical said the problem would arise if the planned trajectory is strictly horizontal. In this case, the insertion of the instrument can lead to tissue damage. As of mid-June 2025, there were no reports of injuries to patients due to the defect described. At the same time, on the specified date, the system helped more than 300 patients around the world.
Quantum Surgical asks all Epione users not to plan trajectories strictly horizontally. The company reminds that the introduction of the tool should begin only after the Robot on Target message is displayed. In the future, the developer will provide a software update that solves the problem.[1]
2023: Product Announcement
On September 7, 2023, French company Quantum Surgical announced the release of the Epione robotic surgical platform to remove malignancies in the lungs.
According to estimates, in 2020, more than 2 million new cases of lung cancer were registered worldwide, including about 500 thousand in Europe. Such tumors are one of the main causes of mortality from malignancies in general. The Epione system allows doctors to effectively eliminate unresectable tumors that are particularly difficult to reach because of their size or location.
Epione is a robotic percutaneous ablation system that uses an automated manipulator, navigation system and camera. The procedures performed are an alternative to surgery. When using Epione, the needle is inserted through the skin into the tumor to kill it. At the same time, Epione combines all stages of the percutaneous ablation procedure on a single platform: this is planning, targeting a malignant formation, destroying and confirming the result.
The Epione system provides for minimally invasive procedures. In addition to eliminating tumors in the lungs, the robot surgeon can be used to treat malignancies in the abdominal cavity, including the liver, kidneys and pancreas. Overall, as noted, Quantum Surgical offers a new approach to cancer therapy.
Epione's platform has received approval from the U.S. Food and Drug Administration (FDA). In addition, CE certification has been passed: this means that the solution meets the basic requirements of the directives and harmonized standards of the European Union. As of September 2023, more than 200 patients have been operated on with Epione in France and the United States.[2]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |